| 1 |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229-263.
|
| 2 |
Dyrskjøt L, Hansel DE, Efstathiou JA, et al. Bladder cancer [J]. Nat Rev Dis Primers, 2023, 9(1): 58.
|
| 3 |
Lenis AT, Lec PM, Chamie K, et al. Bladder Cancer: a review [J]. JAMA, 2020, 324(19): 1980-1991.
|
| 4 |
Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape [J]. Nat Immunol, 2002, 3(11): 991-998.
|
| 5 |
Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy [J]. Science, 2020, 367(6477): eaax0182.
|
| 6 |
Han J, Gu X, Li Y, et al. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect [J]. Biomed Pharmacother, 2020, 129: 110393.
|
| 7 |
Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the massachusetts general hospital experience [J]. Eur Urol, 2017, 71(6): 952-960.
|
| 8 |
Chu C, Pietzak E. Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non-muscle invasive bladder cancer: Invited review for special issue "Seminar: Treatment Advances and Molecular Biology Insights in Urothelial Carcinoma" [J]. Urol Oncol, 2023, 41(10): 398-409.
|
| 9 |
Kraehenbuehl L, Weng CH, Eghbali S, et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways [J]. Nat Rev Clin Oncol, 2022, 19(1): 37-50.
|
| 10 |
Duan T, Du Y, Xing C, et al. Toll-like receptor signaling and its role in cell-mediated immunity [J]. Front Immunol, 2022, 13: 812774.
|
| 11 |
Hannouneh ZA, Hijazi A, Alsaleem AA, et al. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer [J]. Cancer Med, 2023, 12(24): 21944-21968.
|
| 12 |
Fukushima H, Takao S, Furusawa A, et al. Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer [J]. Cancer Lett, 2024, 585: 216606.
|
| 13 |
Kiss B, van den Berg NS, Ertsey R, et al. CD47-targeted near-infrared photoimmunotherapy for human bladder cancer [J]. Clin Cancer Res, 2019, 25(12): 3561-3571.
|
| 14 |
Siddiqui MR, Railkar R, Sanford T, et al. Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) expressing bladder cancer using combination photoimmunotherapy (PIT) [J]. Sci Rep, 2019, 9(1): 2084.
|
| 15 |
Zhang Z, Li D, Yun H, et al. CAR-T cells in the treatment of urologic neoplasms: present and future [J]. Front Oncol, 2022, 12: 915171.
|
| 16 |
Parriott G, Deal K, Crean S, et al. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer [J]. Immunology, 2020, 160(3): 280-294.
|
| 17 |
Ding M, Lin J, Qin C, et al. Novel CAR-T cells specifically targeting SIA-CIgG demonstrate effective antitumor efficacy in bladder cancer [J]. Adv Sci (Weinh), 2024, 11(40): e2400156.
|
| 18 |
MacKay M, Afshinnekoo E, Rub J, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors [J]. Nat Biotechnol, 2020, 38(2): 233-244.
|
| 19 |
Khattak AA, Javed A, Pokhrel P, et al. Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval of Anktiva in combination with BCG [J]. Ann Med Surg (Lond), 2025, 87(2): 457-459.
|
| 20 |
Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines [J]. Eur Urol, 2021, 79(1): 82-104.
|
| 21 |
Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study [J]. J Clin Oncol, 2018, 36(34): 3353-3360.
|
| 22 |
Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial [J]. Nat Med, 2019, 25(11): 1706-1714.
|
| 23 |
Galsky MD, Daneshmand S, Izadmehr S, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial [J]. Nat Med, 2023, 29(11): 2825-2834.
|
| 24 |
Black PC, Tangen CM, Singh P, et al. Phase 2 trial of atezolizumab in bacillus calmette-guérin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605 [J]. Eur Urol, 2023, 84(6): 536-544.
|
| 25 |
Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, et al. Trophy-U-01, a phase Ⅱ open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes [J]. Ann Oncol, 2024, 35(4): 392-401.
|
| 26 |
Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer [J]. N Engl J Med, 2024, 390(10): 875-888.
|
| 27 |
Galsky MD, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from checkmate 274 [J]. J Clin Oncol, 2025, 43(1): 15-21.
|
| 28 |
Dentro SC, Leshchiner I, Haase K, et al. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes [J]. Cell, 2021, 184(8): 2239-2254.e39.
|
| 29 |
Kang HW, Kim WJ, Choi W, et al. Tumor heterogeneity in muscle-invasive bladder cancer [J]. Transl Androl Urol, 2020, 9(6): 2866-2880.
|
| 30 |
da Costa JB, Gibb EA, Nykopp TK, et al. Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy [J]. Urol Oncol, 2022, 40(7): 287-294.
|
| 31 |
Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy [J]. Curr Oncol, 2022, 29(5): 3044-3060.
|
| 32 |
辇伟奇, 聂勇战, 应建明, 等. 肿瘤突变负荷检测及临床应用中国专家共识(2020年版) [J]. 中国癌症防治杂志, 2020, 12(5): 485-494.
|
| 33 |
Jiang T, Chen X, Su C, et al. Pan-cancer analysis of Aridia alterations as biomarkers for immunotherapy outcomes [J]. J Cancer, 2020, 11(4): 776-780.
|
| 34 |
Wang D, Elenbaas B, Murugesan K, et al. Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays [J]. NPJ Precis Oncol, 2023, 7(1): 103.
|
| 35 |
Zhou X, Qiu S, Nie L, et al. Classification of muscle-invasive bladder cancer based on immunogenomic profiling [J]. Front Oncol, 2020, 10: 1429.
|
| 36 |
Bai Y, Wu X, Weng M, et al. The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features [J]. Indian J Pathol Microbiol, 2023, 66(4): 702-707.
|
| 37 |
Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J]. Genome Med, 2017, 9(1): 34.
|
| 38 |
Russo GI, Musso N, Lo Giudice A, et al. PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer [J]. J Cancer Res Clin Oncol, 2023, 149(7): 3681-3690.
|
| 39 |
Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors [J]. Nat Rev Clin Oncol, 2021, 18(6): 345-362.
|
| 40 |
Lu Y, Yuan X, Wang M, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies [J]. J Hematol Oncol, 2022, 15(1): 47.
|